Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Authors:
Crystal S. Denlinger
Search for other papers by Crystal S. Denlinger in
Current site
Google Scholar
PubMed Close
 MD
,
Tara Sanft
Search for other papers by Tara Sanft in
Current site
Google Scholar
PubMed Close
 MD
,
K. Scott Baker
Search for other papers by K. Scott Baker in
Current site
Google Scholar
PubMed Close
 MD, MS
,
Shrujal Baxi
Search for other papers by Shrujal Baxi in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Gregory Broderick
Search for other papers by Gregory Broderick in
Current site
Google Scholar
PubMed Close
 MD
,
Wendy Demark-Wahnefried
Search for other papers by Wendy Demark-Wahnefried in
Current site
Google Scholar
PubMed Close
 PhD, RD
,
Debra L. Friedman
Search for other papers by Debra L. Friedman in
Current site
Google Scholar
PubMed Close
 MD, MS
,
Mindy Goldman
Search for other papers by Mindy Goldman in
Current site
Google Scholar
PubMed Close
 MD
,
Melissa Hudson
Search for other papers by Melissa Hudson in
Current site
Google Scholar
PubMed Close
 MD
,
Nazanin Khakpour
Search for other papers by Nazanin Khakpour in
Current site
Google Scholar
PubMed Close
 MD
,
Allison King
Search for other papers by Allison King in
Current site
Google Scholar
PubMed Close
 MD
,
Divya Koura
Search for other papers by Divya Koura in
Current site
Google Scholar
PubMed Close
 MD
,
Elizabeth Kvale
Search for other papers by Elizabeth Kvale in
Current site
Google Scholar
PubMed Close
 MD
,
Robin M. Lally
Search for other papers by Robin M. Lally in
Current site
Google Scholar
PubMed Close
 PhD, RN, MS
,
Terry S. Langbaum
Search for other papers by Terry S. Langbaum in
Current site
Google Scholar
PubMed Close
 MAS
,
Michelle Melisko
Search for other papers by Michelle Melisko in
Current site
Google Scholar
PubMed Close
 MD
,
Jose G. Montoya
Search for other papers by Jose G. Montoya in
Current site
Google Scholar
PubMed Close
 MD
,
Kathi Mooney
Search for other papers by Kathi Mooney in
Current site
Google Scholar
PubMed Close
 RN, PhD
,
Javid J. Moslehi
Search for other papers by Javid J. Moslehi in
Current site
Google Scholar
PubMed Close
 MD
,
Tracey O'Connor
Search for other papers by Tracey O'Connor in
Current site
Google Scholar
PubMed Close
 MD
,
Linda Overholser
Search for other papers by Linda Overholser in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Electra D. Paskett
Search for other papers by Electra D. Paskett in
Current site
Google Scholar
PubMed Close
 PhD
,
Jeffrey Peppercorn
Search for other papers by Jeffrey Peppercorn in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
M. Alma Rodriguez
Search for other papers by M. Alma Rodriguez in
Current site
Google Scholar
PubMed Close
 MD
,
Kathryn J. Ruddy
Search for other papers by Kathryn J. Ruddy in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Paula Silverman
Search for other papers by Paula Silverman in
Current site
Google Scholar
PubMed Close
 MD
,
Sophia Smith
Search for other papers by Sophia Smith in
Current site
Google Scholar
PubMed Close
 PhD, MSW
,
Karen L. Syrjala
Search for other papers by Karen L. Syrjala in
Current site
Google Scholar
PubMed Close
 PhD
,
Amye Tevaarwerk
Search for other papers by Amye Tevaarwerk in
Current site
Google Scholar
PubMed Close
 MD
,
Susan G. Urba
Search for other papers by Susan G. Urba in
Current site
Google Scholar
PubMed Close
 MD
,
Mark T. Wakabayashi
Search for other papers by Mark T. Wakabayashi in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Phyllis Zee
Search for other papers by Phyllis Zee in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Deborah A. Freedman-Cass
Search for other papers by Deborah A. Freedman-Cass in
Current site
Google Scholar
PubMed Close
 PhD
, and
Nicole R. McMillian
Search for other papers by Nicole R. McMillian in
Current site
Google Scholar
PubMed Close
 MS
Volume/Issue:
Volume 15: Issue 9
Online Publication Date:
Sep 2017
DOI:
https://doi.org/10.6004/jnccn.2017.0146
Restricted access

Many cancer survivors experience menopausal symptoms, including female survivors taking aromatase inhibitors or with a history of oophorectomy or chemotherapy, and male survivors who received or are receiving androgen-ablative therapies. Sexual dysfunction is also common in cancer survivors. Sexual dysfunction and menopause-related symptoms can increase distress and have a significant negative impact on quality of life. This portion of the NCCN Guidelines for Survivorship provide recommendations for screening, evaluation, and treatment of sexual dysfunction and menopausal symptoms to help healthcare professionals who work with survivors of adult-onset cancer in the posttreatment period.

  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Martin K, Barbieri R. Treatment of menopausal symptoms with hormone therapy. Available at: https://www.uptodate.com/contents/treatment-of-menopausal-symptoms-with-hormone-therapy. Accessed August 10, 2017.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 2012;104:386–405.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Nishiyama T, Kanazawa S, Watanabe R et al.. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol 2004;11:735–741.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Chandwani KD, Heckler CE, Mohile SG et al.. Hot flashes severity, complementary and alternative medicine use, and self-rated health in women with breast cancer. Explore (NY) 2014;10:241–247.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Chang HY, Jotwani AC, Lai YH et al.. Hot flashes in breast cancer survivors: frequency, severity and impact. Breast 2016;27:116–121.

  • 6.

    Leining MG, Gelber S, Rosenberg R et al.. Menopausal-type symptoms in young breast cancer survivors. Ann Oncol 2006;17:1777–1782.

  • 7.

    Charig CR, Rundle JS. Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology 1989;33:175–178.

  • 8.

    Freedland SJ, Eastham J, Shore N. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 2009;12:333–338.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Guise TA, Oefelein MG, Eastham JA et al.. Estrogenic side effects of androgen deprivation therapy. Rev Urol 2007;9:163–180.

  • 10.

    Sarosdy MF, Schellhammer PF, Soloway MS et al.. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 1999;83:801–806.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Schow DA, Renfer LG, Rozanski TA, Thompson IM. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 1998;91:855–857.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Walker LM, Tran S, Robinson JW. Luteinizing hormone–releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. Clin Genitourin Cancer 2013;11:375–384.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Autorino R, Perdona S, D'Armiento M et al.. Gynecomastia in patients with prostate cancer: update on treatment options. Prostate Cancer Prostatic Dis 2006;9:109–114.

  • 14.

    Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718–1729.

  • 15.

    De Bruin ML, Huisbrink J, Hauptmann M et al.. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 2008;111:101–108.

  • 16.

    Goodwin PJ, Ennis M, Pritchard KI et al.. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365–2370.

  • 17.

    Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009;360:606–614.

  • 18.

    Skinner R, Mulder RL, Kremer LC et al.. Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Lancet Oncol 2017;18:e75–90.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Krekow LK, Hellerstedt BA, Collea RP et al.. Incidence and predictive factors for recovery of ovarian function in amenorrheic women in their 40s treated with letrozole. J Clin Oncol 2016;34:1594–1600.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Su HI, Sammel MD, Green J et al.. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 2010;116:592–599.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015;22:1155–1172.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Drewe J, Bucher KA, Zahner C. A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. Springerplus 2015;4:65.

  • 23.

    Johns C, Seav SM, Dominick SA et al.. Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. Breast Cancer Res Treat 2016;156:415–426.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Rada G, Capurro D, Pantoja T et al.. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010:CD004923.

  • 25.

    Joffe H, Guthrie KA, LaCroix AZ et al.. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014;174:1058–1066.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Kelsberg G, Maragh L, Safranek S. Clinical inquiry: which nonhormonal treatments are effective for hot flashes? J Fam Pract 2016;65:E1–3.

  • 27.

    Simon JA, Portman DJ, Kaunitz AM et al.. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013;20:1027–1035.

  • 28.

    Barton DL, Loprinzi CL, Novotny P et al.. Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol 2003;1:47–51.

  • 29.

    Capriglione S, Plotti F, Montera R et al.. Role of paroxetine in the management of hot flashes in gynecological cancer survivors: results of the first randomized single-center controlled trial. Gynecol Oncol 2016;143:584–588.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Carpenter JS, Storniolo AM, Johns S et al.. Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist 2007;12:124–135.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Biglia N, Bounous VE, Susini T et al.. Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors. Eur J Cancer Care (Engl) 2016, doi: 10.1111/ecc.12484.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Kimmick GG, Lovato J, McQuellon R et al.. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 2006;12:114–122.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Loprinzi CL, Pisansky TM, Fonseca R et al.. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998;16:2377–2381.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Loprinzi CL, Sloan JA, Perez EA et al.. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578–1583.

  • 35.

    Wu MF, Hilsenbeck SG, Tham YL et al.. The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. Breast Cancer Res Treat 2009;118:369–375.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Ramaswami R, Villarreal MD, Pitta DM et al.. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2015;152:231–237.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Shams T, Firwana B, Habib F et al.. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med 2014;29:204–213.

  • 38.

    Brauch H, Murdter TE, Eichelbaum M, Schwab M. Pharmacogenomics of tamoxifen therapy. Clin Chem 2009;55:1770–1782.

  • 39.

    Haque R, Shi J, Schottinger JE et al.. Tamoxifen and antidepressant drug interaction in a cohort of 16,887 breast cancer survivors. J Natl Cancer Inst 2016;108:djv337.

  • 40.

    Kelly CM, Juurlink DN, Gomes T et al.. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010;340:c693. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20142325.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Butt DA, Lock M, Lewis JE et al.. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause 2008;15:310–318.

  • 42.

    Yurcheshen ME, Guttuso T Jr, McDermott M et al.. Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh Sleep Quality Index factor scoring model. J Womens Health (Larchmt) 2009;18:1355–1360.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Reddy SY, Warner H, Guttuso T Jr et al.. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006;108:41–48.

  • 44.

    Loprinzi CL, Qin R, Balcueva EP et al.. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol 2010;28:641–647.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Pandya KJ, Morrow GR, Roscoe JA et al.. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;366:818–824.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Bordeleau L, Pritchard KI, Loprinzi CL et al.. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010;28:5147–5152.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Laufer LR, Erlik Y, Meldrum DR, Judd HL. Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol 1982;60:583–586.

  • 48.

    Nagamani M, Kelver ME, Smith ER. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Obstet Gynecol 1987;156:561–565.

  • 49.

    Pandya KJ, Raubertas RF, Flynn PJ et al.. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788–793.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Goldberg RM, Loprinzi CL, O'Fallon JR et al.. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155–158.

  • 51.

    Loibl S, Schwedler K, von Minckwitz G et al.. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study. Ann Oncol 2007;18:689–693.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Buijs C, Mom CH, Willemse PH et al.. Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat 2009;115:573–580.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Boekhout AH, Vincent AD, Dalesio OB et al.. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2011;29:3862–3868.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Cramer H, Rabsilber S, Lauche R et al.. Yoga and meditation for menopausal symptoms in breast cancer survivors—a randomized controlled trial. Cancer 2015;121:2175–2184.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Elkins G, Marcus J, Stearns V et al.. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol 2008;26:5022–5026.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Kroenke CH, Caan BJ, Stefanick ML et al.. Effects of a dietary intervention and weight change on vasomotor symptoms in the Women's Health Initiative. Menopause 2012;19:980–988.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Caan BJ, Emond JA, Su HI et al.. Effect of postdiagnosis weight change on hot flash status among early-stage breast cancer survivors. J Clin Oncol 2012;30:1492–1497.

  • 58.

    Stefanopoulou E, Grunfeld EA. Mind-body interventions for vasomotor symptoms in healthy menopausal women and breast cancer survivors. A systematic review. J Psychosom Obstet Gynaecol 2017;38:210–225.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Su HI, Sammel MD, Springer E et al.. Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Res Treat 2010;124:205–211.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Franco OH, Chowdhury R, Troup J et al.. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA 2016;315:2554–2563.

  • 61.

    Quella SK, Loprinzi CL, Barton DL et al.. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group trial. J Clin Oncol 2000;18:1068–1074.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Taku K, Melby MK, Kronenberg F et al.. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause 2012;19:776–790.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Thomas AJ, Ismail R, Taylor-Swanson L et al.. Effects of isoflavones and amino acid therapies for hot flashes and co-occurring symptoms during the menopausal transition and early postmenopause: a systematic review. Maturitas 2014;78:263–276.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Van Patten CL, Olivotto IA, Chambers GK et al.. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 2002;20:1449–1455.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    MacGregor CA, Canney PA, Patterson G et al.. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer 2005;41:708–714.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Sharma P, Wisniewski A, Braga-Basaria M et al.. Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol 2009;182:2265–2272.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Chen WY, Giobbie-Hurder A, Gantman K et al.. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Res Treat 2014;145:381–388.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Dennehy C, Tsourounis C. A review of select vitamins and minerals used by postmenopausal women. Maturitas 2010;66:370–380.

  • 69.

    Laakmann E, Grajecki D, Doege K et al.. Efficacy of Cimicifuga racemosa, Hypericum perforatum and Agnus castus in the treatment of climacteric complaints: a systematic review. Gynecol Endocrinol 2012;28:703–709.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev 2012;9:CD007244.

  • 71.

    Jacobson JS, Troxel AB, Evans J et al.. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19:2739–2745.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Pockaj BA, Gallagher JG, Loprinzi CL et al.. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol 2006;24:2836–2841.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Cho SH, Whang WW. Acupuncture for vasomotor menopausal symptoms: a systematic review. Menopause 2009;16:1065–1073.

  • 74.

    Dodin S, Blanchet C, Marc I et al.. Acupuncture for menopausal hot flushes. Cochrane Database Syst Rev 2013;7:CD007410.

  • 75.

    Garland SN, Xie SX, Li Q et al.. Comparative effectiveness of electro-acupuncture versus gabapentin for sleep disturbances in breast cancer survivors with hot flashes: a randomized trial. Menopause 2017;24:517–523.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Lesi G, Razzini G, Musti MA et al.. Acupuncture as an integrative approach for the treatment of hot flashes in women with breast cancer: a prospective multicenter randomized controlled trial (AcCliMaT). J Clin Oncol 2016;34:1795–1802.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Walker EM, Rodriguez AI, Kohn B et al.. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 2010;28:634–640.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Mao JJ, Bowman MA, Xie SX et al.. Electroacupuncture versus gabapentin for hot flashes among breast cancer survivors: a randomized placebo-controlled trial. J Clin Oncol 2015;33:3615–3620.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Reed SD, Guthrie KA, Newton KM et al.. Menopausal quality of life: RCT of yoga, exercise, and omega-3 supplements. Am J Obstet Gynecol 2014;210:244.e1–11.

  • 80.

    Newton KM, Reed SD, Guthrie KA et al.. Efficacy of yoga for vasomotor symptoms: a randomized controlled trial. Menopause 2014;21:339–346.

  • 81.

    Aiello EJ, Yasui Y, Tworoger SS et al.. Effect of a yearlong, moderate-intensity exercise intervention on the occurrence and severity of menopause symptoms in postmenopausal women. Menopause 2004;11:382–388.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Daley AJ, Thomas A, Roalfe AK et al.. The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial. BJOG 2015;122:565–575.

  • 83.

    Daley A, Stokes-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2014;11:CD006108.

  • 84.

    Lindh-Astrand L, Nedstrand E, Wyon Y, Hammar M. Vasomotor symptoms and quality of life in previously sedentary postmenopausal women randomised to physical activity or estrogen therapy. Maturitas 2004;48:97–105.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Sternfeld B, Guthrie KA, Ensrud KE et al.. Efficacy of exercise for menopausal symptoms: a randomized controlled trial. Menopause 2014;21:330–338.

  • 86.

    Sternfeld B, Dugan S. Physical activity and health during the menopausal transition. Obstet Gynecol Clin North Am 2011;38:537–566.

  • 87.

    Ueda M. A 12-week structured education and exercise program improved climacteric symptoms in middle-aged women. J Physiol Anthropol Appl Human Sci 2004;23:143–148.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Duijts SF, van Beurden M, Oldenburg HS et al.. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol 2012;30:4124–4133.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Smith RL, Flaws JA, Gallicchio L. Does quitting smoking decrease the risk of midlife hot flashes? A longitudinal analysis. Maturitas 2015;82:123–127.

  • 90.

    Peppone LJ, Mustian KM, Morrow GR et al.. The effect of cigarette smoking on cancer treatment-related side effects. Oncologist 2011;16:1784–1792.

  • 91.

    Gallicchio L, Miller SR, Kiefer J et al.. Risk factors for hot flashes among women undergoing the menopausal transition: baseline results from the Midlife Women's Health Study. Menopause 2015;22:1098–1107.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Ayers B, Smith M, Hellier J et al.. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause 2012;19:749–759.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Alder J, Eymann Besken K, Armbruster U et al.. Cognitive-behavioural group intervention for climacteric syndrome. Psychother Psychosom 2006;75:298–303.

  • 94.

    Mann E, Smith MJ, Hellier J et al.. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol 2012;13:309–318.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Baber RJ, Panay N, Fenton AGroup IMSW. 2016 IMS recommendations on women's midlife health and menopause hormone therapy. Climacteric 2016;19:109–150.

  • 96.

    Barnabei VM, Grady D, Stovall DW et al.. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002;100:1209–1218.

  • 97.

    Brunner RL, Aragaki A, Barnabei V et al.. Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause 2010;17:946–954.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    de Villiers TJ, Hall JE, Pinkerton JV et al.. Revised global consensus statement on menopausal hormone therapy. Climacteric 2016;19:313–315.

  • 99.

    Greendale GA, Reboussin BA, Hogan P et al.. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998;92:982–988.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Anderson GL, Limacher M, Assaf AR et al.. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–1712.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Rossouw JE, Anderson GL, Prentice RL et al.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–333.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Chlebowski RT, Wactawski-Wende J, Ritenbaugh C et al.. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350:991–1004.

  • 103.

    Chlebowski RT, Schwartz AG, Wakelee H et al.. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009;374:1243–1251.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Simon MS, Chlebowski RT, Wactawski-Wende J et al.. Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol 2012;30:3983–3990.

  • 105.

    Chlebowski RT, Anderson GL, Gass M et al.. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684–1692.

  • 106.

    Chlebowski RT, Rohan TE, Manson JE et al.. Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women's Health Initiative randomized clinical trials. JAMA Oncol 2015;1:296–305.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Marjoribanks J, Farquhar C, Roberts H et al.. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2017;1:CD004143.

  • 108.

    Barakat RR, Bundy BN, Spirtos NM et al.. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2006;24:587–592.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Chapman JA, DiSaia PJ, Osann K et al.. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:1195–1200.

  • 110.

    Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326–330.

  • 111.

    Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189–191.

  • 112.

    Suriano KA, McHale M, McLaren CE et al.. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 2001;97:555–560.

  • 113.

    Holmberg L, Iversen OE, Rudenstam CM et al.. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475–482.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Fahlen M, Fornander T, Johansson H et al.. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 2013;49:52–59.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Bergendal A, Kieler H, Sundstrom A et al.. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. Menopause 2016;23:593–599.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Kagan R, Williams RS, Pan K et al.. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17:281–289.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    American College of Obstetricians and Gynecologists Committee on Gynecologic Practice American Society for Reproductive Medicine Practice Committee. Compounded bioidentical menopausal hormone therapy. Fertil Steril 2012;98:308–312.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 118.

    Whelan AM, Jurgens TM, Trinacty M. Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective? Ann Pharmacother 2013;47:112–116.

  • 119.

    Biglia N, Peano E, Sgandurra P et al.. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 2010;26:404–412.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Sutton KS, Boyer SC, Goldfinger C et al.. To lube or not to lube: experiences and perceptions of lubricant use in women with and without dyspareunia. J Sex Med 2012;9:240–250.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Loprinzi CL, Abu-Ghazaleh S, Sloan JA et al.. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997;15:969–973.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Nachtigall LE. Comparative study: replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178–180.

  • 123.

    Ayton RA, Darling GM, Murkies AL et al.. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996;103:351–358.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 124.

    Fooladi E, Davis SR. An update on the pharmacological management of female sexual dysfunction. Expert Opin Pharmacother 2012;13:2131–2142.

  • 125.

    Krychman ML. Vaginal estrogens for the treatment of dyspareunia. J Sex Med 2011;8:666–674.

  • 126.

    Raghunandan C, Agrawal S, Dubey P et al.. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med 2010;7:1284–1290.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 127.

    Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006:CD001500.

  • 128.

    Committee Opinion No. 659 summary: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol 2016;127:618–619.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 129.

    Le Ray I, Dell'Aniello S, Bonnetain F et al.. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat 2012;135:603–609.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Trinkaus M, Chin S, Wolfman W et al.. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 2008;13:222–231.

  • 131.

    Wills S, Ravipati A, Venuturumilli P et al.. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 2012;8:144–148.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 132.

    Barton DL, Sloan JA, Shuster LT et al.. Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance) [abstract]. J Clin Oncol 2014;32(Suppl):Abstract 9507.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 133.

    Mazzarello S, Hutton B, Ibrahim MF et al.. Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. Breast Cancer Res Treat 2015;152:1–8.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 134.

    Frisk J. Managing hot flushes in men after prostate cancer—a systematic review. Maturitas 2010;65:15–22.

  • 135.

    Gerber GS, Zagaja GP, Ray PS, Rukstalis DB. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 2000;55:97–101.

  • 136.

    Irani J, Salomon L, Oba R et al.. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 2010;11:147–154.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 137.

    Loprinzi CL, Michalak JC, Quella SK et al.. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347–352.

  • 138.

    Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int 2013;111:543–548.

  • 139.

    Moraska AR, Atherton PJ, Szydlo DW et al.. Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. J Support Oncol 2010;8:128–132.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 140.

    Loprinzi CL, Dueck AC, Khoyratty BS et al.. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol 2009;20:542–549.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 141.

    Quella SK, Loprinzi CL, Sloan J et al.. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999;162:98–102.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 142.

    Ashamalla H, Jiang ML, Guirguis A et al.. Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy. Int J Radiat Oncol Biol Phys 2011;79:1358–1363.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 143.

    Frisk J, Spetz AC, Hjertberg H et al.. Two modes of acupuncture as a treatment for hot flushes in men with prostate cancer—a prospective multicenter study with long-term follow-up. Eur Urol 2009;55:156–163.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 144.

    Stefanopoulou E, Yousaf O, Grunfeld EA, Hunter MS. A randomised controlled trial of a brief cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN). Psychooncology 2015;24:1159–1166.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 145.

    Dueregger A, Heidegger I, Ofer P et al.. The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment. Nutrients 2014;6:4491–4519.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 146.

    Klein EA, Thompson IM Jr, Tangen CM et al.. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306:1549–1556.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 147.

    Peters U, Littman AJ, Kristal AR et al.. Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and Lifestyle (VITAL) study cohort. Cancer Causes Control 2008;19:75–87.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 148.

    Bautista-Vidal C, Barnoiu O, Garcia-Galisteo E et al.. Treatment of gynecomastia in patients with prostate cancer and androgen deprivation. Actas Urol Esp 2014;38:34–40.

  • 149.

    Viani GA, Bernardes da Silva LG, Stefano EJ. Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy? Int J Radiat Oncol Biol Phys 2012;83:e519–524.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 150.

    Bober SL, Varela VS. Sexuality in adult cancer survivors: challenges and intervention. J Clin Oncol 2012;30:3712–3719.

  • 151.

    Donovan KA, Thompson LM, Hoffe SE. Sexual function in colorectal cancer survivors. Cancer Control 2010;17:44–51.

  • 152.

    Jackson SE, Wardle J, Steptoe A, Fisher A. Sexuality after a cancer diagnosis: a population-based study. Cancer 2016;122:3883–3891.

  • 153.

    Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537–544.

  • 154.

    Morreale MK. The impact of cancer on sexual function. Adv Psychosom Med 2011;31:72–82.

  • 155.

    Vomvas D, Iconomou G, Soubasi E et al.. Assessment of sexual function in patients with cancer undergoing radiotherapy—a single centre prospective study. Anticancer Res 2012;32:657–664.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 156.

    Bober SL, Carter J, Falk S. Addressing female sexual function after cancer by internists and primary care providers. J Sex Med 2013;10(Suppl 1):112–119.

  • 157.

    Forbat L, White I, Marshall-Lucette S, Kelly D. Discussing the sexual consequences of treatment in radiotherapy and urology consultations with couples affected by prostate cancer. BJU Int 2012;109:98–103.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 158.

    Reese JB, Sorice K, Beach MC et al.. Patient-provider communication about sexual concerns in cancer: a systematic review. J Cancer Surviv 2017;11:175–188.

  • 159.

    Sporn NJ, Smith KB, Pirl WF et al.. Sexual health communication between cancer survivors and providers: how frequently does it occur and which providers are preferred? Psychooncology 2015;24:1167–1173.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 160.

    White ID, Allan H, Faithfull S. Assessment of treatment-induced female sexual morbidity in oncology: is this a part of routine medical follow-up after radical pelvic radiotherapy? Br J Cancer 2011;105:903–910.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 161.

    ACOG Practice Bulletin No. 119: female sexual dysfunction. Obstet Gynecol 2011;117:996–1007.

  • 162.

    Gilbert E, Ussher JM, Perz J. Sexuality after breast cancer: a review. Maturitas 2010;66:397–407.

  • 163.

    Krychman M, Millheiser LS. Sexual health issues in women with cancer. J Sex Med 2013;10(Suppl 1):5–15.

  • 164.

    Barni S, Mondin R. Sexual dysfunction in treated breast cancer patients. Ann Oncol 1997;8:149–153.

  • 165.

    Frumovitz M, Sun CC, Schover LR et al.. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 2005;23:7428–7436.

  • 166.

    Ganz PA, Desmond KA, Belin TR et al.. Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 1999;17:2371–2380.

  • 167.

    Ganz PA, Rowland JH, Desmond K et al.. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501–514.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 168.

    Lindau ST, Gavrilova N, Anderson D. Sexual morbidity in very long term survivors of vaginal and cervical cancer: a comparison to national norms. Gynecol Oncol 2007;106:413–418.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 169.

    Park SY, Bae DS, Nam JH et al.. Quality of life and sexual problems in disease-free survivors of cervical cancer compared with the general population. Cancer 2007;110:2716–2725.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 170.

    Rodrigues AC, Teixeira R, Teixeira T et al.. Impact of pelvic radiotherapy on female sexuality. Arch Gynecol Obstet 2012;285:505–514.

  • 171.

    Gershenson DM, Miller AM, Champion VL et al.. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study. J Clin Oncol 2007;25:2792–2797.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 172.

    Lammerink EA, de Bock GH, Pras E et al.. Sexual functioning of cervical cancer survivors: a review with a female perspective. Maturitas 2012;72:296–304.

  • 173.

    Fobair P, Stewart SL, Chang S et al.. Body image and sexual problems in young women with breast cancer. Psychooncology 2006;15:579–594.

  • 174.

    Syrjala KL, Kurland BF, Abrams JR et al.. Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years. Blood 2008;111:989–996.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 175.

    Thygesen KH, Schjodt I, Jarden M. The impact of hematopoietic stem cell transplantation on sexuality: a systematic review of the literature. Bone Marrow Transplant 2012;47:716–724.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 176.

    Watson M, Wheatley K, Harrison GA et al.. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Cancer 1999;86:1231–1239.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 177.

    Zantomio D, Grigg AP, MacGregor L et al.. Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for management. Bone Marrow Transplant 2006;38:567–572.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 178.

    NIH consensus conference. Impotence. NIH consensus development panel on impotence. JAMA 1993;270:83–90.

  • 179.

    Montague DK, Jarow JP, Broderick GA et al.. Erectile Dysfunction. American Urological Association, 2005. Available at: http://www.auanet.org/education/guidelines/erectile-dysfunction.cfm. Accessed May 3, 2017.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 180.

    Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res 2005;17:307–319.

  • 181.

    Monga M, Bettencourt R, Barrett-Connor E. Community-based study of erectile dysfunction and sildenafil use: the Rancho Bernardo study. Urology 2002;59:753–757.

  • 182.

    Ellis R, Smith A, Wilson S et al.. The prevalence of erectile dysfunction in post-treatment colorectal cancer patients and their interests in seeking treatment: a cross-sectional survey in the west-midlands. J Sex Med 2010;7:1488–1496.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 183.

    Hendren SK, O'Connor BI, Liu M et al.. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg 2005;242:212–223.

  • 184.

    Potosky AL, Davis WW, Hoffman RM et al.. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004;96:1358–1367.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 185.

    Resnick MJ, Koyama T, Fan KH et al.. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013;368:436–445.

  • 186.

    Schover LR, Fouladi RT, Warneke CL et al.. Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer 2002;95:1773–1785.

  • 187.

    Siegel T, Moul JW, Spevak M et al.. The development of erectile dysfunction in men treated for prostate cancer. J Urol 2001;165:430–435.

  • 188.

    Stanford JL, Feng Z, Hamilton AS et al.. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000;283:354–360.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 189.

    Loren AW, Mangu PB, Beck LN et al.. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2500–2510.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 190.

    Armuand GM, Wettergren L, Rodriguez-Wallberg KA, Lampic C. Desire for children, difficulties achieving a pregnancy, and infertility distress 3 to 7 years after cancer diagnosis. Support Care Cancer 2014;22:2805–2812.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 191.

    Kort JD, Eisenberg ML, Millheiser LS, Westphal LM. Fertility issues in cancer survivorship. CA Cancer J Clin 2014;64:118–134.

  • 192.

    Murphy D, Orgel E, Termuhlen A et al.. Why healthcare providers should focus on the fertility of AYA cancer survivors: it's not too late! Front Oncol 2013;3:248.

  • 193.

    Quinn MM, Letourneau JM, Rosen MP. Contraception after cancer treatment: describing methods, counseling, and unintended pregnancy risk. Contraception 2014;89:466–471.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 194.

    Bartula I, Sherman KA. Development and validation of the Female Sexual Function Index adaptation for breast cancer patients (FSFI-BC). Breast Cancer Res Treat 2015;152:477–488.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 195.

    Hatzichristou D, Rosen RC, Derogatis LR et al.. Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med 2010;7:337–348.

  • 196.

    McGahuey CA, Gelenberg AJ, Laukes CA et al.. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25–40.

  • 197.

    Rosen R, Brown C, Heiman J et al.. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 198.

    Abraham L, Symonds T, Morris MF. Psychometric validation of a sexual quality of life questionnaire for use in men with premature ejaculation or erectile dysfunction. J Sex Med 2008;5:595–601.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 199.

    Assessment Center. Available at: http://www.assessmentcenter.net/. Accessed May 3, 2017.

    • PubMed
    • Export Citation
  • 200.

    Baser RE, Li Y, Carter J. Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors. Cancer 2012;118:4606–4618.

  • 201.

    Jeffery DD, Tzeng JP, Keefe FJ et al.. Initial report of the cancer Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function committee: review of sexual function measures and domains used in oncology. Cancer 2009;115:1142–1153.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 202.

    Bartula I, Sherman KA. Screening for sexual dysfunction in women diagnosed with breast cancer: systematic review and recommendations. Breast Cancer Res Treat 2013;141:173–185.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 203.

    Flynn P, Kew F, Kisely SR. Interventions for psychosexual dysfunction in women treated for gynaecological malignancy. Cochrane Database Syst Rev 2009:CD004708.

  • 204.

    Katz A. Interventions for sexuality after pelvic radiation therapy and gynecological cancer. Cancer J 2009;15:45–47.

  • 205.

    Brotto LA, Erskine Y, Carey M et al.. A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. Gynecol Oncol 2012;125:320–325.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 206.

    Hummel SB, van Lankveld JJ, Oldenburg HS et al.. Efficacy of internet-based cognitive behavioral therapy in improving sexual functioning of breast cancer survivors: results of a randomized controlled trial. J Clin Oncol 2017;35:1328–1340.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 207.

    Hickey M, Marino JL, Braat S, Wong S. A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer. Breast Cancer Res Treat 2016.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 208.

    Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol 2015;33:3394–3400.

  • 209.

    Yang EJ, Lim JY, Rah UW, Kim YB. Effect of a pelvic floor muscle training program on gynecologic cancer survivors with pelvic floor dysfunction: a randomized controlled trial. Gynecol Oncol 2012;125:705–711.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 210.

    Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst Rev 2010:CD007291.

  • 211.

    Melisko ME, Goldman ME, Hwang J et al.. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol 2017;3:313–319.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 212.

    Archer DF, Labrie F, Bouchard C et al.. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause 2015;22:950–963.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 213.

    Archer DF, Labrie F, Montesino M, Martel C. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10mcg estradiol on symptoms of vulvovaginal atrophy. J Steroid Biochem Mol Biol 2017, pii: S0960-0760(17)30079-1.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 214.

    Labrie F, Archer DF, Bouchard C et al.. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric 2011;14:282–288.

  • 215.

    Labrie F, Archer DF, Koltun W et al.. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 2016;23:243–256.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 216.

    Labrie F, Archer DF, Bouchard C et al.. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas 2015;81:46–56.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 217.

    Scheffers CS, Armstrong S, Cantineau AE et al.. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst Rev 2015;1:CD011066.

  • 218.

    INTRAROSA (prasterone) vaginal inserts. Shionogi Inc.; 2016. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208470s000lbl.pdf. Accessed April 28, 2017.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 219.

    OSPHENA (ospemifene). Shionogi Inc.; 2015. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203505s005lbl.pdf. Accessed May 3, 2017.

  • 220.

    Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17:480–486.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 221.

    Goldstein SR, Bachmann GA, Koninckx PR et al.. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014;17:173–182.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 222.

    Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20:623–630.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 223.

    ADDYI (flibanserin). Sprout Pharmaceuticals, Inc.; 2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf. Accessed May 3, 2017.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 224.

    Jaspers L, Feys F, Bramer WM et al.. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med 2016;176:453–462.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 225.

    Gao Z, Yang D, Yu L, Cui Y. Efficacy and safety of flibanserin in women with hypoactive sexual desire disorder: a systematic review and meta-analysis. J Sex Med 2015;12:2095–2104.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 226.

    Goldstein I, Kim NN, Clayton AH et al.. Hypoactive sexual desire disorder: International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc 2017;92:114–128.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 227.

    Segraves RT, Croft H, Kavoussi R et al.. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J Sex Marital Ther 2001;27:303–316.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 228.

    Segraves RT, Clayton A, Croft H et al.. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol 2004;24:339–342.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 229.

    Landen M, Eriksson E, Agren H, Fahlen T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1999;19:268–271.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 230.

    Cavalcanti AL, Bagnoli VR, Fonseca AM et al.. Effect of sildenafil on clitoral blood flow and sexual response in postmenopausal women with orgasmic dysfunction. Int J Gynaecol Obstet 2008;102:115–119.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 231.

    Yang CC, Cao YY, Guan QY et al.. Influence of PDE5 inhibitor on MRI measurement of clitoral volume response in women with FSAD: a feasibility study of a potential technique for evaluating drug response. Int J Impot Res 2008;20:105–110.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 232.

    Alexander MS, Rosen RC, Steinberg S et al.. Sildenafil in women with sexual arousal disorder following spinal cord injury. Spinal Cord 2011;49:273–279.

  • 233.

    Basson R, McInnes R, Smith MD et al.. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002;11:367–377.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 234.

    Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. BJOG 2003;110:1014–1024.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 235.

    Berman JR, Berman LA, Toler SM et al.. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. J Urol 2003;170:2333–2338.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 236.

    Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BJOG 2001;108:623–628.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 237.

    Caruso S, Rugolo S, Agnello C et al.. Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. Fertil Steril 2006;85:1496–1501.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 238.

    Esposito K, Giugliano F, Di Palo C et al.. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004;291:2978–2984.

  • 239.

    Lamina S, Okoye CG, Dagogo TT. Therapeutic effect of an interval exercise training program in the management of erectile dysfunction in hypertensive patients. J Clin Hypertens (Greenwich) 2009;11:125–129.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 240.

    Khoo J, Piantadosi C, Duncan R et al.. Comparing effects of a low-energy diet and a high-protein low-fat diet on sexual and endothelial function, urinary tract symptoms, and inflammation in obese diabetic men. J Sex Med 2011;8:2868–2875.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 241.

    Khoo J, Piantadosi C, Worthley S, Wittert GA. Effects of a low-energy diet on sexual function and lower urinary tract symptoms in obese men. Int J Obes (Lond) 2010;34:1396–1403.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 242.

    Maio G, Saraeb S, Marchiori A. Physical activity and PDE5 inhibitors in the treatment of erectile dysfunction: results of a randomized controlled study. J Sex Med 2010;7:2201–2208.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 243.

    Andersson E, Walen C, Hallberg J et al.. A randomized controlled trial of guided Internet-delivered cognitive behavioral therapy for erectile dysfunction. J Sex Med 2011;8:2800–2809.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 244.

    Aubin S, Heiman JR, Berger RE et al.. Comparing sildenafil alone vs. sildenafil plus brief couple sex therapy on erectile dysfunction and couples' sexual and marital quality of life: a pilot study. J Sex Marital Ther 2009;35:122–143.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 245.

    Banner LL, Anderson RU. Integrated sildenafil and cognitive-behavior sex therapy for psychogenic erectile dysfunction: a pilot study. J Sex Med 2007;4:1117–1125.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 246.

    Boddi V, Castellini G, Casale H et al.. An integrated approach with vardenafil orodispersible tablet and cognitive behavioral sex therapy for treatment of erectile dysfunction: a randomized controlled pilot study. Andrology 2015;3:909–918.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 247.

    Wylie KR. Treatment outcome of brief couple therapy in psychogenic male erectile disorder. Arch Sex Behav 1997;26:527–545.

  • 248.

    Canada AL, Neese LE, Sui D, Schover LR. Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma. Cancer 2005;104:2689–2700.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 249.

    Schover LR, Canada AL, Yuan Y et al.. A randomized trial of internet-based versus traditional sexual counseling for couples after localized prostate cancer treatment. Cancer 2012;118:500–509.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 250.

    Fink HA, Mac Donald R, Rutks IR et al.. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002;162:1349–1360.

  • 251.

    Nehra A. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc 2009;84:139–148.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 252.

    Hubanks JM, Umbreit EC, Karnes RJ, Myers RP. Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series. Eur Urol 2012;61:878–884.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 253.

    Yang L, Qian S, Liu L et al.. Phosphodiesterase-5 inhibitors could be efficacious in the treatment of erectile dysfunction after radiotherapy for prostate cancer: a systematic review and meta-analysis. Urol Int 2012;90:339–347.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 254.

    Kloner RA, Hutter AM, Emmick JT et al.. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003;42:1855–1860.

  • 255.

    Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999;83:21C–28C.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 256.

    Zhao C, Kim SW, Yang DY et al.. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60:380–387.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 257.

    Rajfer J, Aliotta PJ, Steidle CP et al.. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 2007;19:95–103.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 258.

    Porst H, Giuliano F, Glina S et al.. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006;50:351–359.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 259.

    Shim YS, Pae CU, Cho KJ et al.. Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study. Int J Impot Res 2014;26:76–80.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 260.

    Bhasin S, Cunningham GR, Hayes FJ et al.. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–2559.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 261.

    Snyder PJ, Bhasin S, Cunningham GR et al.. Effects of testosterone treatment in older men. N Engl J Med 2016;374:611–624.

  • 262.

    Cunningham GR, Stephens-Shields AJ, Rosen RC et al.. Testosterone treatment and sexual function in older men with low testosterone levels. J Clin Endocrinol Metab 2016;101:3096–3104.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 263.

    Buvat J, Montorsi F, Maggi M et al.. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 2011;8:284–293.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 264.

    Corona G, Vignozzi L, Sforza A, Maggi M. Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health 2013;31:103–125.

  • 265.

    Khera M, Bhattacharya RK, Blick G et al.. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med 2011;8:3204–3213.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 266.

    Rosenthal BD, May NR, Metro MJ et al.. Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 2006;67:571–574.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 267.

    Hwang TI, Chen HE, Tsai TF, Lin YC. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res 2006;18:400–404.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 268.

    Zitzmann M, Mattern A, Hanisch J et al.. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 2013;10:579–588.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 269.

    Campbell SE, Glazener CM, Hunter KF et al.. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev 2012;1:CD001843.

  • 270.

    Geraerts I, Van Poppel H, Devoogdt N et al.. Pelvic floor muscle training for erectile dysfunction and climacturia 1 year after nerve sparing radical prostatectomy: a randomized controlled trial. Int J Impot Res 2016;28:9–13.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 271.

    Prota C, Gomes CM, Ribeiro LH et al.. Early postoperative pelvic-floor biofeedback improves erectile function in men undergoing radical prostatectomy: a prospective, randomized, controlled trial. Int J Impot Res 2012;24:174–178.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 272.

    Nelson CJ, Ahmed A, Valenzuela R et al.. Assessment of penile vibratory stimulation as a management strategy in men with secondary retarded orgasm. Urology 2007;69:552–555; discussion 555–556.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 273.

    Cooper K, Martyn-St James M, Kaltenthaler E et al.. Interventions to treat premature ejaculation: a systematic review short report. Health Technol Assess 2015;19:1–180.

  • 274.

    Giuliano F, Clement P. Pharmacology for the treatment of premature ejaculation. Pharmacol Rev 2012;64:621–644.

  • 275.

    Kim SC, Seo KK. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol 1998;159:425 –427.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 276.

    Waldinger MD, Zwinderman AH, Olivier B. On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment. Eur Urol 2004;46:510 –515; discussion 516.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2017 by the National Comprehensive Cancer Network 2017
Page Numbers:
24
Article Category:
Research Article
Print Publication Date:
01 Sep 2017
Online Publication Date:
Sep 2017

Metrics

All Time Past Year Past 30 Days
Abstract Views 1 0 0
Full Text Views 11292 4524 966
PDF Downloads 3258 623 44
EPUB Downloads 0 0 0